BACKGROUND: The gene for preferentially expressed antigen of melanoma (PRAME) has been shown to be over-expressed in acute promyelocytic leukemia, but its actual incidence and clinical impact are still unknown. DESIGN AND METHODS: We studied PRAME expression at diagnosis using real-time quantitative polymerase chain reaction in 125 patients with acute promyelocytic leukemia enrolled in the Spanish PETHEMA-96 (n=45) and PETHEMA-99 (n=80) clinical trials. In addition, PRAME expression was evaluated as a marker of disease activity in 225 follow-up samples from 67 patients with acute promyelocytic leukemia. RESULTS: At diagnosis, PRAME expression in patients with acute promyelocytic leukemia was significantly higher (p<0.001) than in patients with non-M3 acute myeloid leukemia (n=213) and in healthy controls (n=10). Furthermore, patients with acute promyelocytic leukemia with high PRAME expression had a favorable outcome. Thus, the 5-year relapse-free survival was better in patients with >100-fold PRAME expression (86% vs. 74%; p=0.03), and this cut-off established two sub-groups with different relapse-free survival rates among patients with a white cell count <10(9)/L (5-year relapse-free survival 94% vs. 80%, p=0.01). This effect was similar in patients with a white cell count >10(9)/L, although differences were not statistically significant. In multivariate analysis, white cell count >10(9)/L (p<0.001), bone marrow blasts >90% (p=0.001), and PRAME expression <100-fold (p=0.009) were associated with short relapse-free survival. Samples at remission showed PRAME levels similar to those in normal controls while samples at relapse over-expressed PRAME again. Furthermore, 12/13 samples collected within the 6-month period preceding relapse showed a >10-fold increase in PRAME expression levels. CONCLUSIONS: Low PRAME expression defines a subgroup of patients with acute promyelocytic leukemia with a short relapse-free survival. This marker could be useful as a secondary marker for monitoring patients with acute promyelocytic leukemia.
BACKGROUND: The gene for preferentially expressed antigen of melanoma (PRAME) has been shown to be over-expressed in acute promyelocytic leukemia, but its actual incidence and clinical impact are still unknown. DESIGN AND METHODS: We studied PRAME expression at diagnosis using real-time quantitative polymerase chain reaction in 125 patients with acute promyelocytic leukemia enrolled in the Spanish PETHEMA-96 (n=45) and PETHEMA-99 (n=80) clinical trials. In addition, PRAME expression was evaluated as a marker of disease activity in 225 follow-up samples from 67 patients with acute promyelocytic leukemia. RESULTS: At diagnosis, PRAME expression in patients with acute promyelocytic leukemia was significantly higher (p<0.001) than in patients with non-M3 acute myeloid leukemia (n=213) and in healthy controls (n=10). Furthermore, patients with acute promyelocytic leukemia with high PRAME expression had a favorable outcome. Thus, the 5-year relapse-free survival was better in patients with >100-fold PRAME expression (86% vs. 74%; p=0.03), and this cut-off established two sub-groups with different relapse-free survival rates among patients with a white cell count <10(9)/L (5-year relapse-free survival 94% vs. 80%, p=0.01). This effect was similar in patients with a white cell count >10(9)/L, although differences were not statistically significant. In multivariate analysis, white cell count >10(9)/L (p<0.001), bone marrow blasts >90% (p=0.001), and PRAME expression <100-fold (p=0.009) were associated with short relapse-free survival. Samples at remission showed PRAME levels similar to those in normal controls while samples at relapse over-expressed PRAME again. Furthermore, 12/13 samples collected within the 6-month period preceding relapse showed a >10-fold increase in PRAME expression levels. CONCLUSIONS: Low PRAME expression defines a subgroup of patients with acute promyelocytic leukemia with a short relapse-free survival. This marker could be useful as a secondary marker for monitoring patients with acute promyelocytic leukemia.
Authors: Jessica A Hemminger; Amanda Ewart Toland; Thomas J Scharschmidt; Joel L Mayerson; Denis C Guttridge; O Hans Iwenofu Journal: Mod Pathol Date: 2014-01-24 Impact factor: 7.842
Authors: María Carmen Chillón; Carlos Santamaría; Ramón García-Sanz; Ana Balanzategui; María Eugenia Sarasquete; Miguel Alcoceba; Luis Marín; María Dolores Caballero; María Belén Vidriales; Fernando Ramos; Teresa Bernal; Joaquín Díaz-Mediavilla; Alfonso García de Coca; María Jesús Peñarrubia; José Antonio Queizán; Pilar Giraldo; Jesús F San Miguel; Marcos González Journal: Haematologica Date: 2010-02-04 Impact factor: 9.941
Authors: Frances Wadelin; Joel Fulton; Paul A McEwan; Keith A Spriggs; Jonas Emsley; David M Heery Journal: Mol Cancer Date: 2010-08-27 Impact factor: 27.401
Authors: Vivian G Oehler; Katherine A Guthrie; Carrie L Cummings; Kathleen Sabo; Brent L Wood; Ted Gooley; Taimei Yang; Mirjam T Epping; Yaping Shou; Era Pogosova-Agadjanyan; Paula Ladne; Derek L Stirewalt; Janis L Abkowitz; Jerald P Radich Journal: Blood Date: 2009-07-22 Impact factor: 22.113
Authors: L Dyrskjøt; K Zieger; T Kissow Lildal; T Reinert; O Gruselle; T Coche; M Borre; T F Ørntoft Journal: Br J Cancer Date: 2012-05-17 Impact factor: 7.640
Authors: Adalberto Costessi; Nawel Mahrour; Vikram Sharma; Rieka Stunnenberg; Marieke A Stoel; Esther Tijchon; Joan W Conaway; Ronald C Conaway; Hendrik G Stunnenberg Journal: PLoS One Date: 2012-08-13 Impact factor: 3.240